$TG治疗(TGTX)$ MS数据很不错!$BioNTech(BNTX)$ $Editas Medicine(EDIT)$
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis
Both studies met their primary endpoint of significantly reducing annualized relapse rate (ARR) (p<0.005 in each study) with ublituximab demonstrating an ARR of <0.10 in each of the studies
Relative reductions of approximately 60% and 50% in ARR over teriflunomide were observed in ULTIMATE I & II, respectively
Detailed data presentation targeted in 1H 2021 with a BLA submission targeted mid-year 2021